HUTCHMED (China) Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HUTCHMED (China) Limited
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
Hutchmed is in discussions with the European Medicines Agency on the path forward for its drug for advanced neuroendocrine tumors, whose marketing authorization application has now been withdrawn.
An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.
- Other Names / Subsidiaries
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited